Status:
UNKNOWN
A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Marfan Syndrome
Eligibility:
All Genders
1+ years
Phase:
PHASE2
Brief Summary
To assess the efficacy of angiotensin II receptor blocker, Losartan, to prevent progressive dilation of aortic root in patients with Marfan syndrome.
Detailed Description
Marfan syndrome (MFS) is a multisystem connective tissue disorder of autosomal dominant inheritance1. The cardinal features are noted in the cardiovascular, ocular, and skeletal system. The most life-...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Marfan syndrome with recognized aortic root dilation
- Patients must be older than one year of age
- Beta-blocker treatment at least three months
- Must sign an informed consent form
- Exclusion criteria
- Prior to aortic root surgery
- Aortic root dimension more than 5.5cm
- Aortic surgery within 6 months
- Diabetes mellitus or liver and renal dysfunction or asthma
- Pregnancy
- Intolerance to Losartan therapy
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00651235
Start Date
February 1 2007
End Date
June 1 2011
Last Update
June 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100